FDA Inspection 1310244 — Shilpa Gupta, M.D.
The FDA completed an inspection of Shilpa Gupta, M.D. on Mar 20, 2026 in Cleveland, OH. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection details
- Classification
- No Action Indicated (NAI)
- End Date
- Mar 20, 2026
- Fiscal Year
- 2026
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Cleveland, OH (United States)
Additional details
Clinical Investigator (CI)